Sahar Mashayekhi Firouz

Sahar Mashayekhi Firouz

Auto-generated profile, based on publicly available information

Sahar Mashayekhi Firouz

Department of Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2023 in BioImpacts
Verified
Journal Article
Open access
MSMaryam Sayahinouri
Maryam Sayahinouri
SFSahar Mashayekhi Firouz
Sahar Mashayekhi Firouz
ASAmin Ebrahimi Sadrabadi
Amin Ebrahimi Sadrabadi
MMMina Masoudnia
Mina Masoudnia
MAMahnaz Abdolahi
Mahnaz Abdolahi
NANasser Aghdami
Nasser Aghdami
Introduction: In late December 2019, a sudden severe respiratory illness of unknown origin was reported in China. In early January 2020, the cause of COVID-19 infection was announced a new coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Examination of the SARS-CoV-2 genome sequence revealed a close resemblance to the previously reported SARS-CoV and coronavirus Middle East respiratory syndrome (MERS-CoV). However, initial testing of drugs used against SARS-CoV and MERS-CoV has been ineffective in controlling SARS-CoV-2. One of the key strategies to fight the virus is to look at how the immune system works against the virus, which has led to a better understanding of the disease and the development of new therapies and vaccine designs. Methods: This review discussed the innate and acquired immune system responses and how immune cells function against the virus to shed light on the human body's defense strategies. Results: Although immune responses have been revealed critical to eradicating infections caused by coronaviruses, dysregulated immune responses can lead to immune pathologies thoroughly investigated. Also, the benefit of mesenchymal stem cells, NK cells, Treg cells, specific T cells, and platelet lysates have been submitted as promising solutions to prevent the effects of infection in patients with COVID-19. Conclusion: It has been concluded that none of the above has undoubtedly been approved for the treatment or prevention of COVID-19, but clinical trials are underway better to understand the efficacy and safety of these cellular therapies.

1 January 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JXJi Xu
Ji Xu
SFSahar Mashayekhi Firouz
Sahar Mashayekhi Firouz
MFMina Farrokhian
Mina Farrokhian
SGShadi Ghoreishizadeh
Shadi Ghoreishizadeh
DMDr. Talar Ahmad Ahmad Merza Mohammad
Dr. Talar Ahmad Ahmad Merza Mohammad
ASAli Sadeghian Shahi
Ali Sadeghian Shahi